Dong Shixia, Liu Kunjing, Liu Ruijuan, Zhuang Jing
Clinical Medical Colleges, Weifang Medical University, Weifang, Shandong 261053, P.R. China.
College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong 250014, P.R. China.
Exp Ther Med. 2022 Aug 8;24(4):617. doi: 10.3892/etm.2022.11554. eCollection 2022 Oct.
Immunotherapy through blocking programmed cell death 1, programmed death-ligand 1 and cytotoxic T lymphocyte antigen 4 is developing rapidly and has gained increasing attention as a treatment for malignant tumors. However, some patients experience varying degrees of immune-related side effects after undergoing immunotherapy, with hyperprogressive disease (HPD) occurring in severe cases which increases the risk of mortality. The present study discussed the risk factors for HPD following immunotherapy in a case of lung squamous cell carcinoma, after treatment with a combination of anti-angiogenic drugs and biological cytotoxic drugs, the mass was found to have become smaller than before, along with follow-up treatment options, to provide a reference for clinical treatment decisions.
通过阻断程序性细胞死亡蛋白1、程序性死亡配体1和细胞毒性T淋巴细胞相关抗原4进行的免疫疗法发展迅速，作为一种恶性肿瘤治疗方法已受到越来越多的关注。然而，一些患者在接受免疫治疗后会出现不同程度的免疫相关副作用，严重时会发生超进展性疾病（HPD），这增加了死亡风险。本研究探讨了1例肺鳞状细胞癌患者免疫治疗后发生HPD的危险因素，在联合使用抗血管生成药物和生物细胞毒性药物治疗后，发现肿块比以前变小，同时探讨了后续治疗方案，为临床治疗决策提供参考。
